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OBJECTIVE: To compare the cost-effectiveness of rosuvastatin
(RSV) with those of atorvastatin (ATV), pravastatin (PRA) and
simvastatin (SIM) in achieving National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) goal by 
lowering low-density lipoprotein cholesterol (LDL-C) levels.
METHODS: The study was conducted from the perspective of
private payers in Mexico. Clinical data were obtained from
STELLAR trial, in which 2268 adult patients received a ﬁxed
dose of RSV 10, 20, 40 or 80 mg/day for 6 weeks; ATV 10, 20,
40 or 80 mg/day; SIM 10, 20, 40, 80 mg/day; or PRA 10, 20 or
40 mg/day. In Mexico only RSV 10 and 20 mg are commercial-
ized, hence the analysis was done with the latter doses. Annual
costs (treatment and maintenance) were based on acquisition
costs for the drug as reported by NADRO (local wholesaler) on
March 2006. Cost effectiveness was assessed with the net mon-
etary beneﬁt approach (NMB) and a 1-year time horizon. Results
were graphed out using the cost-effectiveness acceptability curve.
A sensitivity analysis was conducted to consider the effect of
price discounting in the Mexican Market. RESULTS: RSV is
found to be more effective and less costly than ATV, SIM and
PRA at reducing LDL-C.RSV at 10 mg/day was the most cost-
effective statin when addressing the ATP III goals ($0 to $601.43
USD), while for higher k values -the value placed on the clinical
effect in monetary terms-, RSV 20 mg was most cost effective
therapy. The sensitivity analysis revealed RSV 10 and 20 mg/day
were the most cost-effective statins for the substantial price
decreases of alternative statins scenario. CONCLUSIONS: In
order to achieve NCEP ATP III LDL-C goals, RSV 10 and 20
mg/day provided the greatest value for money compared with
ATV, PRA and SIM in Mexico.
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OBJECTIVE: Effective cholesterol-lowering therapy is needed in
order to reduce the risk of cardiovascular disease in patients with
high levels of LDL-cholesterol, especially in high-risk groups
such as patients with diabetes or a history of heart disease. Clin-
ical trials have showed that rosuvastatin is an effective choles-
terol-lowering medication, but it is also important to assess its
cost-effectiveness. METHODS: The cost-effectiveness of choles-
terol-lowering therapy with rosuvastatin compared to atorvas-
tatin, simvastatin, and pravastatin was estimated with a Markov
model of cardiovascular disease. The model simulated the occur-
rence of revascularization procedures, myocardial infarction,
and stroke. Health effects were measured in terms of quality
adjusted life years (QALYs). RESULTS: Cholesterol-lowering
therapy with rosuvastatin was found to be cost-saving and asso-
ciated with better effect (QALYs) compared to atorvastatin and
pravastatin. For patients with prior heart disease and no addi-
tional risk factor incremental cost per QALY gained of rosuvas-
tatin 10 mg compared to simvastatin 20 mg was 825,000 SEK
for 70 year-old men, and 901,000 SEK for 70 year old women.
For patients with both coronary heart disease and diabetes the
cost-effectiveness ratios compared to simvastatin were 415,000
SEK per QALY for 70 year-old men, and 459,000 SEK per QALY
for 70 year-old women. CONCLUSION: The results indicate
that cholesterol-lowering therapy with rosuvastatin is cost saving
compared to atorvastatin and pravastatin among patients with
prior coronary heart disease or diabetes. Compared to simvas-
tatin cholesterol-lowering therapy with rosuvastatin could be
cost-effective under certain conditions, in particular in high risk
patients with two or more risk factors for cardiovascular disease.
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OBJECTIVE: To evaluate, in the Swedish setting, the cost-
effectiveness of raising low high-density lipoprotein-cholesterol
(HDL-c) with Niaspan® on top of statin-based therapy, in type
2 diabetes (T2D) patients with persistently low HDL-c levels.
METHODS: We used a simulation model made of 2 decision
analytic sub-models. The ﬁrst sub-model (second order Monte-
carlo simulations) generated patient’s cohort and simulated lipid
changes after treatment. Baseline cohort characteristics were
taken from a Pan-European Survey on HDL-c prevalence
(Swedish diabetic sub-group). Niaspan® treatment effects were
taken from the ARBITER II study. Patients with low HDL-c
(<1.03 mmol/L) on statin treatment received either add-on
Niaspan® (1 g/day) or continued statin alone. The second sub-
model (Markov) calculated the risk of coronary heart disease
events based on Framingham risk formulae. Direct medical costs
(SEK) were accounted from a third-party payer perspective.
Annual discount rates of 3% were applied to costs and clinical
beneﬁts. Simulations were run to capture patient lifetimes.
RESULTS: Niaspan® + statin was associated with an increase in
discounted life expectancy (0.20 years) compared to statin alone.
Direct medical costs were on average SEK34,320 higher in the
Niaspan® + statin group leading to an Incremental Cost-Effec-
tiveness Ratio of SEK169,696 per Life Year Gained (ICER <
SEK190,000/LYG is highly cost-effective). CONCLUSION: In
the Swedish setting, raising HDL-c with the addition of Niaspan®
to statin treatment increases life expectancy and is highly cost-
effective compared to statin monotherapy in T2D patients with
dyslipidemia and persistently low HDL-c.
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OBJECTIVES: Several health economic studies have shown
clopidogrel to be cost-effective in preventing ischemic events in
non-ST-segment elevation myocardial infarction (NSTEMI) and
unstable angina. The objective of this study was to evaluate the
long-term cost-effectiveness of clopidogrel in ST-segment eleva-
tion MI (STEMI) based on data from the CLARITY and
